Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Quest PharmaTech Inc.

Market Cap 5.92M 4.18M 3.64M 3.37M 3.16M 394M 5.96M 40M 15.5M 194M 15.67M 15.34M 673M P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 6.91M 4.87M 4.25M 3.93M 3.68M 460M 6.95M 46.66M 18.08M 226M 18.28M 17.89M 785M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
Current month-3.23%
1 month-1.32%
3 months+125.56%
6 months+125.56%
Current year+125.56%
1 week 0.03
Extreme 0.03
0.03
1 month 0.03
Extreme 0.03
0.03
Current year 0.03
Extreme 0.03
0.03
1 year 0.03
Extreme 0.03
0.03
3 years 0.01
Extreme 0.0133
0.04
5 years 0.01
Extreme 0.0133
0.08
10 years 0.01
Extreme 0.0133
0.24
Manager TitleAgeSince
Chief Executive Officer - 2004-06-16
Director of Finance/CFO - 2004-12-31
Director TitleAgeSince
Director/Board Member - 2004-06-16
Chairman - 2021-07-04
Director/Board Member - 2021-07-04
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 4.18M
+1.44%+1.71%-10.98%-6.19% 43.13B
+3.31%+5.93%+310.97%+534.70% 34.65B
+2.84%+2.14%+9.34%+41.02% 30.03B
-1.70%-7.54%+8.43%-21.94% 28B
-1.90%-1.56%+10.24%+21.21% 24.45B
-0.14%+5.86% - - 14.34B
+0.68%-1.53%+48.76%+104.27% 13.14B
-0.57%-2.43%+5.08%+4.79% 12.53B
-0.26%+1.15%+98.13%+80.47% 12.25B
Average +0.37%+0.73%+60.00%+94.79% 23.61B
Weighted average by Cap. +0.77%+1.27%+65.47%+110.06%

Financials

2025 2026
Net sales - -
Net income -1.8M -1.27M -1.11M -1.03M -960K -120M -1.81M -12.17M -4.72M -59M -4.77M -4.67M -205M 5M 3.53M 3.07M 2.85M 2.67M 333M 5.03M 33.77M 13.09M 164M 13.23M 12.95M 569M
Net Debt 795K 561K 489K 453K 424K 52.91M 800K 5.37M 2.08M 26.04M 2.1M 2.06M 90.42M 986K 695K 606K 561K 526K 65.6M 992K 6.66M 2.58M 32.29M 2.61M 2.55M 112M
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume
26-06-17 0.0300 $ 0.00% 50,000
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!